Siemens Fonds Invest’s BioMarin Pharmaceuticals BMRN Stock Holding History

Siemens Fonds Invest’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,579	Closed	-$140K	–	549
2025 Q3	$140K	Buy	2,579 +10	+0.4%	+$572	0.01%	514
2025 Q2	$141K	Buy	2,569 +507	+25%	+$29.9K	0.01%	505
2025 Q1	$146K	Buy	+2,062	New	+$139K	0.01%	488

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Siemens Fonds Invest's BMRN Position: Q4 2025 in Review

Siemens Fonds Invest sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 2,579 shares — an estimated $140K sold.

Siemens Fonds Invest first reported a position in BMRN in Q1 2025 and held it in 3 quarters. The position peaked at $146K in Q1 2025. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Siemens Fonds Invest reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Siemens Fonds Invest sold 2,579 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $140K.
Siemens Fonds Invest first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 3 quarters.
Siemens Fonds Invest's BioMarin Pharmaceuticals position peaked at $146K in Q1 2025.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Siemens Fonds Invest's 13F filing for Q4 2025, filed 17 Feb 2026.